Extension Study Evaluating Etanercept in Ankylosing Spondylitis
NCT ID: NCT00410046
Last Updated: 2012-05-11
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
84 participants
INTERVENTIONAL
2006-12-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open-Label Multicentre Long-Term Extension Study of Etanercept for Ankylosing Spondylitis
NCT00444340
Study Evaluating Etanercept for the Treatment of Active, Severe, and Advanced Axial Ankylosing Spondylitis
NCT00420238
An Open-Label, Multicentre, Long-Term Extension Study of Etanercept in Ankylosing Spondylitis
NCT00421980
Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis
NCT00544557
Study Evaluating Etanercept in Subjects With Ankylosing Spondylitis in Spain
NCT00873730
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Etanercept (ETN)
Patients received ETN dose 50 mg once weekly or Sulphasalazine dose 3 g daily in study 402 for 16 weeks. Upon enrollment into study 405, all received subcutaneous injections of etanercept 50 mg once weekly for 36 weeks.
Enbrel (etanercept)
Etanercept 50 mg SC injection once weekly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enbrel (etanercept)
Etanercept 50 mg SC injection once weekly
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wyeth
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth Reserach
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fredriksberg, , Denmark
Odense, , Denmark
Svendborg, , Denmark
Vejle, , Denmark
Helsinki, , Finland
Hyvinkää, , Finland
Kuopio, , Finland
Tampere, , Finland
Stockholm, , Sweden
Basingstoke, , United Kingdom
Bath, , United Kingdom
Cambridge, , United Kingdom
Cannock, , United Kingdom
Liverpool, , United Kingdom
Metropolitan Borough of Wirral, , United Kingdom
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Baraliakos X, Szumski AE, Kwok KK, Vlahos B, Borlenghi CE. Long-term Etanercept Response for Patients with Radiographic Axial Spondyloarthritis Based on Achievement of Early, Intermediate, or Late Responses During Index Studies. Rheumatol Ther. 2024 Jun;11(3):583-597. doi: 10.1007/s40744-024-00656-3. Epub 2024 Mar 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0881A3-405
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.